# SCRN2

## Overview
SCRN2 is a gene that encodes the secernin 2 protein, which is primarily involved in the regulation of secretion and exocytosis within cells. Secernin 2 is a cytoplasmic protein that plays a pivotal role in vesicle trafficking and membrane fusion, processes essential for the release of cellular contents such as neurotransmitters and hormones into the extracellular space. This protein is crucial for maintaining cellular homeostasis and facilitating effective cellular communication and immune responses. Beyond its fundamental cellular functions, SCRN2 has been implicated in various pathological conditions, including cardiovascular diseases and cancer, through its influence on cholesterol metabolism and potential involvement in tumorigenesis (Glicksberg2019Integrative; BernardoCastiñeira2019Epigenetic). Additionally, secernin 2's role in mRNA decay and protein localization further underscores its significance in cellular biology and disease mechanisms (Gilbertson2018Changes).

## Function
The SCRN2 gene encodes the secernin 2 protein, which plays a crucial role in various cellular processes, particularly in secretion and exocytosis. This protein is involved in regulating vesicle trafficking and membrane fusion, essential for maintaining cellular homeostasis. SCRN2 is active in the cytoplasm, where it influences the movement and fusion of vesicles with cellular membranes, facilitating the release of cellular contents into the extracellular space. This function is vital for processes such as neurotransmitter release, hormone secretion, and the delivery of membrane proteins to the cell surface.

In addition to its role in vesicle trafficking, SCRN2 may also impact immune responses and cellular communication. By modulating the secretion of signaling molecules, SCRN2 can influence how cells interact with each other and respond to external stimuli. This regulatory function is important for maintaining the balance of cellular activities and ensuring proper physiological responses to environmental changes. The activity of SCRN2 in these processes underscores its significance in cell biology and its potential impact on organismal health by contributing to effective cellular communication and immune function.

## Clinical Significance
SCRN2 has been implicated in various diseases and conditions through alterations in its expression and interactions. In cardiovascular research, SCRN2 has been identified as a candidate gene for plasma cholesterol-lowering effects. Silencing SCRN2 in HepG2 cells resulted in reduced levels of Apolipoprotein B-100 (APOB-100) and Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9), while increasing the expression of the LDL receptor (LDLR), suggesting its role in hepatic cholesterol homeostasis and potential as a target for lowering plasma cholesterol (Glicksberg2019Integrative).

In cancer research, SCRN2 has been found to be hypermethylated in pheochromocytomas and paragangliomas associated with SDHB mutations, indicating a potential role in tumorigenesis. The hypermethylation of SCRN2 in these tumors suggests its involvement in cancer-related pathways, although the exact mechanisms remain to be fully elucidated (BernardoCastiñeira2019Epigenetic).

Additionally, SCRN2's involvement in exocytosis and its translocation to the nucleus in the absence of Xrn1 highlights its potential role in cellular processes related to mRNA decay and protein localization, which could have implications in various diseases (Gilbertson2018Changes).


## References


[1. (Glicksberg2019Integrative) Benjamin S. Glicksberg, Letizia Amadori, Nicholas K. Akers, Katyayani Sukhavasi, Oscar Franzén, Li Li, Gillian M. Belbin, Kristin L. Akers, Khader Shameer, Marcus A. Badgeley, Kipp W. Johnson, Ben Readhead, Bruce J. Darrow, Eimear E. Kenny, Christer Betsholtz, Raili Ermel, Josefin Skogsberg, Arno Ruusalepp, Eric E. Schadt, Joel T. Dudley, Hongxia Ren, Jason C. Kovacic, Chiara Giannarelli, Shuyu D. Li, Johan L. M. Björkegren, and Rong Chen. Integrative analysis of loss-of-function variants in clinical and genomic data reveals novel genes associated with cardiovascular traits. BMC Medical Genomics, July 2019. URL: http://dx.doi.org/10.1186/s12920-019-0542-3, doi:10.1186/s12920-019-0542-3. This article has 7 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s12920-019-0542-3)

[2. (BernardoCastiñeira2019Epigenetic) Cristóbal Bernardo-Castiñeira, Nuria Valdés, Lucía Celada, Andrés San José Martinez, I Sáenz-de-Santa-María, Gustavo F Bayón, Agustín F Fernández, Marta I Sierra, Mario F Fraga, Aurora Astudillo, Paula Jiménez-Fonseca, Juan Carlos Rial, Miguel Ángel Hevia, Estrella Turienzo, Carmen Bernardo, Lluis Forga, Isabel Tena, María-José Molina-Garrido, Laura Cacho, Carles Villabona, Teresa Serrano, Bartolomé Scola, Isabel Chirivella, Maribel del Olmo, Carmen Luz Menéndez, Elena Navarro, María Tous, Ana Vallejo, Shobana Athimulam, Irina Bancos, Carlos Suarez, and María-Dolores Chiara. Epigenetic deregulation of protocadherin pcdhgc3 in pheochromocytomas/paragangliomas associated with sdhb mutations. The Journal of Clinical Endocrinology &amp; Metabolism, 104(11):5673–5692, June 2019. URL: http://dx.doi.org/10.1210/jc.2018-01471, doi:10.1210/jc.2018-01471. This article has 10 citations.](https://doi.org/10.1210/jc.2018-01471)

[3. (Gilbertson2018Changes) Sarah Gilbertson, Joel D Federspiel, Ella Hartenian, Ileana M Cristea, and Britt Glaunsinger. Changes in mrna abundance drive shuttling of rna binding proteins, linking cytoplasmic rna degradation to transcription. eLife, October 2018. URL: http://dx.doi.org/10.7554/elife.37663, doi:10.7554/elife.37663. This article has 104 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.7554/elife.37663)